OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 2.

Table. 2.

Characteristics of enrolled participants according to categorization of cystatin C-based eGFR with Gentiancys and Gentianeq

Parameter Categorization of cystatin C-based eGFR with Gentiancys and Gentianeq*

G1 (N=44) G2 (N=36) G3 (N=31) G4 (N=20) G5 (N=17) Total (N=148)
Age, yr, mean ± SD 58.4 ± 14.9 61.0 ± 11.7 57.8 ± 14.9 62.5 ± 17.7 67.8 ± 12.7 60.5 ± 14.5
Age range, yr 20–85 36–82 20–81 27–91 49–88 20–91
Female, N (%) 22 (50) 12 (33) 13 (42) 8 (40) 8 (47) 63 (43)
ICU admission, N (%) 14 (32) 7 (19) 13 (42) 7 (35) 9 (53) 50 (34)
Acute kidney injury, N (%) 0 (0) 2 (6) 3 (10) 3 (15) 4 (24) 12 (8)
Hemodialysis or CRRT, N (%) 0 (0) 1 (3) 4 (13) 4 (20) 7 (41) 16 (11)
Creatinine, mg/dL, mean ± SD 0.63 ± 0.20 0.90 ± 0.29 1.04 ± 0.4 1.43 ± 0.52 3.37 ± 1.68 1.20 ± 1.04
eGFR CKD-EPICrea, mL/min/1.73 m2, mean ± SD 105.0 ± 19.6 84.3 ± 20.7 74.5 ± 26.0 55.2 ± 26.2 24.0 ± 22.4 77.5 ± 33.7
Gentiancys value, mg/L, mean ± SD 0.72 ± 0.11 1.09 ± 0.08 1.51 ± 0.18 2.37 ± 0.36 5.24 ± 1.22 1.72 ± 1.44
Rochecys value, mg/L, mean ± SD 0.80 ± 0.10 1.12 ± 0.08 1.50 ± 0.18 2.29 ± 0.36 5.03 ± 1.03 1.71 ± 1.35
eGFR with Gentiancys and Gentianeq, mL/min/1.73 m2, mean ± SD 133.9 ± 30.0 70.9 ± 8.1 45.1 ± 7.7 23.9 ± 4.8 8.1 ± 2.6 70.7 ± 48.8

*According to the 2012 KDIGO classification, each eGFR value was categorized as eGFR ≥90 mL/min/1.73 m2 (G1), 60–89 mL/min/1.73 m2 (G2), 30–59 mL/min/1.73 m2 (G3), 15–29 mL/min/1.73 m2 (G4), or<15 mL/min/1.73 m2 (G5).

Abbreviations: eGFR, estimated glomerular filtration rate; Gentianeq, the equation of Gentian manufacturer; Gentiancys, Gentian cystatin C immunoassay; ICU, intensive care unit; CRRT, continuous renal replacement therapy; CKD-EPIcys, CKD-EPI cystatin C equation; CKD-EPIcrea, CKD-EPI creatinine equation; Rochecys, Tina-quant Gen.2 assay.

Ann Lab Med 2023;43:565~573 https://doi.org/10.3343/alm.2023.43.6.565

© Ann Lab Med